Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.

WARNING: DISTRESSING CONTENT Andre Thomas murdered his ex-wife Laura Boren and her two young children in a frenzied knife attack in 2004, before mutilating their bodies and gouging out his own eyes ...

Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results ...

It may feel like there’s an overwhelming amount of products we’re told to add to our skincare routines, especially as we age. While you might not actually need to devote an entire shelf of your ...